Based on this evidence, a clinical trial on toripalimab in patients with several solid tumours, including CRC, with POLE mutations and non-MSI-H, has been initiated (NCT03810339) (Wang et al., 2019). This evidence concerns the gene POLE and colorectal carcinoma.